PRDX4, peroxiredoxin 4, 10549

N. diseases: 59; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia
0.300 Therapeutic disease CTD_human Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. 20446767 2010
CUI: C0271650
Disease: Impaired glucose tolerance
Impaired glucose tolerance
0.300 Therapeutic phenotype CTD_human Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. 20446767 2010
CUI: C1855520
Disease: Hyperglycemia, Postprandial
Hyperglycemia, Postprandial
0.300 Therapeutic phenotype CTD_human Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. 20446767 2010
CUI: C0079744
Disease: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
0.300 Biomarker disease CTD_human A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. 16081686 2005
CUI: C0162820
Disease: Dermatitis, Allergic Contact
Dermatitis, Allergic Contact
0.300 Biomarker disease CTD_human Gene transcripts as potential diagnostic markers for allergic contact dermatitis. 16033404 2005
CUI: C0235874
Disease: Disease Exacerbation
Disease Exacerbation
0.300 Biomarker phenotype CTD_human A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. 16081686 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 Biomarker group BEFREE And it has been demonstrated that peroxiredoxin 4 causally contributes to tumorigenesis, therapeutic resistance, metastasis, and recurrence of tumors. 31311441 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE We previously reported that peroxiredoxin 4 (PRDX4), a secretory-type antioxidant enzyme, can protect against the development of various diseases, including potential malignancies. 30013444 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis. 25779674 2015
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 AlteredExpression group BEFREE Our results demonstrated that the expression of Prx IV was induced as cells became competent to synthesize immunoglobulin light chains, as observed by immunohistochemistry in tissue sections of B cell neoplasms and also by qPCR and Western blotting analyses in malignant B cell lines. 23737084 2013
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 AlteredExpression group BEFREE Reverse phase protein arrays verified that the overexpression of both PRDX3 and PRDX4 in tumor samples is negatively correlated with the presence of the TMPRSS2-ERG gene fusion. 22424448 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Our work reveals that the Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment. 21487000 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 Biomarker group BEFREE Disruption or enhancement of the Srx-Prx IV axis leads respectively to reduction or acceleration of tumor growth and metastasis formation in vivo. 21487000 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.050 AlteredExpression group BEFREE Immunohistochemical analysis revealed significantly higher levels of PRDX4 and P4HA2 in tumor cells than adjacent non-tumor epithelia (P < 0.0001 and P < 0.0001, respectively), and even higher expression in the 31 metastatic tumors of lymph nodes, compared to the corresponding primary tumors (P = 0.060 and P = 0.002, respectively). 21859152 2011
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE Investigation of peroxiredoxin IV as a calpain-regulated pathway in cancer. 21187494 2010
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.050 Biomarker group BEFREE These results suggested that Prx IV involved in the 16alpha-OHE1-induced proliferation of MCF-7 cells has a proliferative effect and may be related to cancer development or progression. 18272409 2008
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.040 Biomarker phenotype BEFREE Targeting of PRDX4 may represent a promising strategy to block HCC cell growth and metastasis. 31256347 2019
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.040 AlteredExpression phenotype BEFREE Moreover, high expression of PRDX4 in the primary breast tumor was consistently associated with metastasis at 5 years. 25779674 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis. 25779674 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.040 AlteredExpression phenotype BEFREE Immunohistochemical analysis revealed significantly higher levels of PRDX4 and P4HA2 in tumor cells than adjacent non-tumor epithelia (P < 0.0001 and P < 0.0001, respectively), and even higher expression in the 31 metastatic tumors of lymph nodes, compared to the corresponding primary tumors (P = 0.060 and P = 0.002, respectively). 21859152 2011
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.040 Biomarker phenotype BEFREE Disruption or enhancement of the Srx-Prx IV axis leads respectively to reduction or acceleration of tumor growth and metastasis formation in vivo. 21487000 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Our work reveals that the Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment. 21487000 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Investigation of peroxiredoxin IV as a calpain-regulated pathway in cancer. 21187494 2010
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE These results suggested that Prx IV involved in the 16alpha-OHE1-induced proliferation of MCF-7 cells has a proliferative effect and may be related to cancer development or progression. 18272409 2008
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder)
0.030 AlteredExpression disease BEFREE The combination of the PRDX4 expression level with the EGFR mutation status was closely associated with the prognosis of patients with stage I LUAD. 31588184 2019